CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
Ceribell, Inc. (CBLL) reported that President and CEO, and director, Xingjuan Chao exercised stock options for a total of 25,000 shares of Common Stock at an exercise price of $4.70 per share on September 2, 2026, and on the same date sold 39,540 shares of Common Stock at a weighted average price of $24.61 per share in transactions effected pursuant to a Rule 10b5-1 trading plan.
Following these transactions, 369,088 shares of Common Stock are reported as held indirectly through the ACP 2021 Trust, where Chao is a co-trustee and may be deemed to share beneficial ownership, while disclaiming beneficial ownership except to the extent of her pecuniary interest.
Ceribell, Inc. insider activity shows that on September 2, 2026, Chief Financial Officer Scott Blumberg exercised a fully vested stock option to acquire 652 shares of common stock at an exercise price of $9.41 per share and then sold 652 shares of common stock at $25.00 per share. After this option exercise, he continued to hold 52,648 stock options directly. All reported transactions were effected under a Rule 10b5-1 trading plan adopted on December 12, 2025.
Ceribell, Inc. (CBLL) shareholder Xingjuan Chao has filed a notice of proposed sale of restricted or control securities under Rule 144. The filing covers 39,540 shares of common stock, to be sold through Fidelity Brokerage Services LLC, with an approximate aggregate market value of $973,090.39 as of September 2, 2026.
The shares relate to stock options exercised on April 30, 2018, May 15, 2025, and September 2, 2026. Ceribell reports 38,378,101 shares of common stock outstanding, providing context for the size of this planned sale.
Ceribell, Inc. (CBLL) has a notice of proposed resale of restricted or control securities under Rule 144 filed on behalf of officer Scott E. Blumberg. The notice covers the planned sale of 652 shares of common stock, to be sold through Fidelity Brokerage Services LLC, with an indicated value of $16,300.00 as of September 2, 2026, in connection with a stock option exercise for cash. The filing also lists prior sales by Scott E. Blumberg over the past three months, including 990 shares for $24,750.00 on August 18, 2026, 33,512 shares for $838,819.52 on August 19, 2026, and 1,521 shares for $36,537.15 on August 21, 2026.
Ceribell, Inc. (CBLL) reported that Chief Revenue Officer Joseph S. Manni sold 1,361 shares of common stock on 2026-08-21 at $24.02 per share. According to the disclosure, these shares were sold to cover tax withholding obligations related to vesting restricted stock units. After this transaction, he directly held 55,956 shares, which includes 1,026 shares acquired through Ceribell's Employee Stock Purchase Plan on 2026-07-31.
Ceribell, Inc. (CBLL) reported insider transactions by David Foehr, Senior VP, Finance and PAO. On August 21, 2026, he sold 993 shares of common stock at $24.02 per share to cover tax withholding obligations related to vesting RSUs. On August 24, 2026, he sold 859 shares of common stock at $23.95 per share in an open-market or private transaction effected pursuant to a Rule 10b5-1 trading plan. Both transactions involved directly held shares.
Ceribell, Inc. (CBLL) reported an insider transaction by Chief Technology Officer Raymond Woo. On August 21, 2026, Woo sold 1,979 shares of common stock at $24.02 per share in a sale used to cover tax withholding obligations related to vesting restricted stock units. After this transaction, Woo directly held 194,729 shares of common stock, which includes 1,026 shares acquired under Ceribell's Employee Stock Purchase Plan on July 31, 2026.
Ceribell, Inc. (CBLL) reported that Chief Financial Officer Scott Blumberg sold shares of common stock. On 2026-08-21, he sold 1,521 shares at $24.02 per share in a transaction described as a sale in the open market or a private transaction. According to the footnote, these shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units. After this transaction, Blumberg directly holds 146,600 shares of Ceribell common stock.
Ceribell, Inc. (CBLL) director and President & CEO Chao Xingjuan reported selling 6,068 shares of common stock on 2026-08-21 at $24.02 per share. According to a footnote, these shares were sold to cover tax withholding obligations arising from vesting of restricted stock units. After this sale, she directly held 781,731 shares. A separate holding entry reports an additional 369,088 shares held indirectly through the ACP 2021 Trust, where she is a co-trustee and may be deemed to share beneficial ownership but disclaims ownership beyond her pecuniary interest. The Rule 10b5-1 checkbox was not marked as a plan transaction.
Ceribell, Inc. (symbol CBLL) is the issuer of common stock that David Foehr plans to sell under Rule 144. The notice lists 859 shares of common stock held at Fidelity Brokerage Services LLC, with an aggregate market value of $20,573.05 and trading on NASDAQ.
The securities to be sold originate from restricted stock vesting dated August 20, 2026 and are classified as compensation from the issuer. Over the prior three months, a separate sale of 993 common shares for aggregate proceeds of $23,853.64 on August 21, 2026 is also reported for David J. Foehr.